BLAB — Britannia Life Sciences Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeMicro CapValue Trap

Annual cashflow statement for Britannia Life Sciences, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.

	C2018 November 30th	2019 November 30th	2020 November 30th	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-11.9	-7.13	-3.2	-14	5.84
Depreciation
Deferred Taxes
Non-Cash Items	7.4	1.69	2.18	16.1	-4.45
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	0.178	-1.72	0.75	0.461	-0.415
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-3.97	-7.11	-0.207	2.8	1.22
Capital Expenditures	-0.712	-0.068	0	-0.087	-0.342
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.167	0	—	0.741	-2.98
Acquisition of Business
Sale of Business
Purchase of Investments
Cash from Investing Activities	-0.544	-0.068	0	0.654	-3.32
Financing Cash Flow Items	—	—	1.93	-0.596	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	7.32	3.55	0.022	-2.58	2.95
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	2.81	-3.62	-0.185	0.803	0.967